James M. Cornelius - 12 Sep 2024 Form 3 Insider Report for MBX Biosciences, Inc. (MBX)

Role
Director
Signature
/s/ Richard Bartram, attorney-in-fact
Issuer symbol
MBX
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
3
Filing time
12 Sep 2024, 19:23:08 UTC
Next filing
17 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MBX Stock Option (right to buy) 12 Sep 2024 Common Stock 16,636 $0.4900 Direct F1
holding MBX Stock Option (right to buy) 12 Sep 2024 Common Stock 22,641 $9.14 Direct F2
holding MBX Series A Convertible Preferred Stock 12 Sep 2024 Common Stock 82,686 Direct F3
holding MBX Series B Convertible Preferred Stock 12 Sep 2024 Common Stock 19,396 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of September 1, 2020, subject to the Reporting Person's continued service on each such vesting date.
F2 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 31, 2024, subject to the Reporting Person's continued service on each such vesting date.
F3 Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") is convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney